AFC Energy launches its dedicated Anion Exchange Membrane Fuel Cell test facility

AFC Energy plc (LON:AFC), a leading provider of hydrogen power generation technologies, has announced the launch of its dedicated Anion Exchange Membrane Fuel Cell test facility hosted at the Company’s Surrey headquarters in the United Kingdom.   

Highlights

·      AFC Energy’s high energy-dense fuel cell technology, HydroX-Cell(S), has been strengthened by the launch of a world class AEM fuel cell testing and diagnostic facility in the UK.

·      Design of the new dedicated AEM fuel cell facility was completed in the second half of 2020 with full fit out now complete in advance of full operation. 

·      The “S” Series AEM hydrogen fuel cell, once complete, will create the option for heavy motive applications to deploy alkaline chemistry fuel cells in marine, rail and other heavy motive applications, with cost benefits derived particularly from low capital cost and fuel flexibility.

·      The AEM facility will enhance the timely feedback in performance of the AlkaMem® anion exchange membrane in fuel cell applications, further enhancing our development of the membrane for use in other markets.    

·      The new facility will also support AFC Energy’s work in the integration of an in-house developed anionic conducting ionomer within the AEM electrode which offers higher ion exchange capacity, and therefore improved fuel cell performance. 

·      Pilot fabrication processes for the production of Membrane Electrode Assemblies (MEA) are now fully established within AFC Energy and the fabrication method enables consistent MEA production.

·      These advancements support the “S” Series Fuel Cell technology remaining on target for initial release in late 2022.

AFC Energy has continued to make positive steps along its roadmap to release of a pre commercial prototype of its new, high power density HydroX-Cell(S)TM fuel cell system.  AFC Energy has maintained the progress in the development of its AlkaMemTM anion exchange membrane during Q3 / Q4 2020 despite some challenges arising due to impacts caused by the ongoing COVID-19 pandemic.

Since the June 2020 update the Company’s has designed and today launches its new HydroX-Cell(S)TM Fuel Cell research facility to support the rapid work scheduled to meet our development plans.

Initial design work has concluded on the stack design for the “S” Series AEM fuel cell based upon our scaled up MEA. Final build of this unit will be completed in April and will provide the set-up needed to validate the design criteria for the modular 10 kW HydroX-Cell(S)TM fuel cell stack. The Company has stated its plans to release early commercial scale HydroX-Cell(S)TM stacks to the market in late 2022 and remains on track to achieve this timeline.

The work being undertaken on AlkaMem has been equally pleasing in terms of  the developments made; whether in relation to enhancing membrane mechanical strength, improving the performance and stability of our ionomer, meeting the challenge of producing consistent MEAs or tuning the preparation steps to enable a range of membrane thicknesses to be offered. These developments by the team have maintained the pace needed to achieve our end objectives.

Adam Bond, Chief Executive Officer of AFC Energy, said:

“Our new world class AEM hydrogen fuel cell research facility cements AFC Energy at the cutting edge of arguably the world’s most promising, low cost, high energy dense fuel cell technology.  We continue to believe this platform will compete head on with incumbent high energy dense fuel cells in the market today such as PEM technologies both on cost and performance, but with all the benefits of our proprietary alkaline chemistry.” 

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    AFC Energy

    More articles like this

    Fintel plc

    Fintel Plc appoint Phil Smith as Non-Executive Director

    Fintel plc (LON: FNTL), the leading provider of Fintech and support services to the UK retail financial services sector, has announced the appointment of Phil Smith as Independent Non-Executive Director with immediate effect. Following a robust process led

    Pendragon plc

    Pendragon underlying Profit before Tax of £18.7m, up 73.1%

    Pendragon plc (LON:PDG) has announced its interim management statement. This Interim Management Statement covers the period from 1 January 2022 to 31 March 2022.  Unless otherwise stated, figures quoted in this statement are for the three

    SpaceandPeople returns to profit

    SpaceandPeople plc (LON:SAL) secures, sells, and manages flexible space for brand experiences, short term promotions and retailing in high footfall venues for its customers, including in shopping centres and travel hubs. The Group has issued full

    SpaceandPeople back into profit and positive earnings per share

    SpaceandPeople plc (LON:SAL) the retail, promotional and brand experience specialist, has announced its final results for the year ended 31 December 2021.   Financial Highlights ·       Revenue of £4.0 million (2020: £2.8 million and 2019: £7.7 million) ·       Operating profit of

    tinyBuild plc

    tinyBuild acquihires development studio Demagic Games

    tinyBuild plc (LON:TBLD), a premium video games publisher and developer with global operations, has announced the acquihire of Demagic Games, a development studio with 23 staff[1] currently based in Ukraine and Russia. The Company has been working

    Vertu Motors Plc

    Vertu Motors share buyback programme update

    Vertu Motors plc (LON: VTU) has announced that on 07 April 2022, it purchased 201,999 ordinary shares of 10p each in the Company on the London Stock Exchange, pursuant to the share buyback programme that was announced on 2nd March 2022 as

    Oncimmune Holdings report two further ImmunoINSIGHTS contracts signed

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer

    Lookers Plc

    Lookers shares to trade in excess of 150p says Zeus

    Lookers plc (LON:LOOK) has announced FY21 results that show record underlying PBT of £90.7m, 5.3% above our forecast of £86.2m. The outlook is suitably cautious given current supply constraints and likely impact of inflation on future